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ABSTRACT
The increasing structural information about target-
bound compounds provide a rich basis to study the
binding mechanisms of metabolites and drugs.
SuperSite is a database, which combines the struc-
tural information with various tools for the analysis
of molecular recognition. The main data is made up
of 8000 metabolites including 1300 drugs, bound to
about 290000 different receptor binding sites. The
analysis tools include features, like the highlighting
of evolutionary conserved receptor residues, the
marking of putative binding pockets and the super-
positioning of different binding sites of the same
ligand. User-defined compounds can be edited or
uploaded and will be superimposed with the most
similar co-crystallized ligand. The user can examine
all results online with the molecule viewer Jmol. An
implemented search algorithm allows the screening
of uploaded proteins, in order to detect potential
drug binding sites, which are similar to known bind-
ing pockets. The huge data set of target-bound
compounds in combination with the provided analy-
sis tools allow to inspect the characteristics of
molecular recognition, especially for drug target
interactions. SuperSite is publicly available at:
http://bioinformatics.charite.de/supersite.
INTRODUCTION
The Protein Data Bank (1) contains crystallographic
information about proteins, which are co-crystallized
with thousands of metabolites or drugs. The data are
highly relevant not only for analyzing the recognition of
individual compounds (2), but also as a learning set for
molecular interaction models (3). In many cases, small
compounds bound to macromolecules are medically
active and listed as approved drugs. The consideration
of such co-crystallized structures can considerably facili-
tate the process of drug development (4). Another impor-
tant aspect of molecular interaction is the speciﬁcity of a
ligand. Many compounds address several receptor pro-
teins. Comparative analysis of the target proteins can
enable to draw conclusions about the molecular recogni-
tion between ligands and targets (5). One paradigm, that
frequently reoccurs, is the concept of structure activity
relationship (SAR)—either meaning, that similar ligands
have a similar mode of action (6), or that similar binding
sites may share binding partners. This paradigm has impli-
cations for ﬁnding novel leads, as well as the elucidation of
possible side eﬀects (7). SitesBase (8) is an excellent source,
which utilizes this similarity concept, using an indexing
algorithm, that allows fast comparisons of similar binding
sites. This enables the researcher to quickly generate
hypotheses about probabilities that a certain binding site
will be adopted by a ligand. For further investigations of
the interactions between small compounds and macro-
molecules, a variety of additional sources are available.
Concerning experimentally available binding data like
Kd, Ki and IC50 data, the Binding MOAD (9),
PDBbind (10) and the Binding Database (11) are of spe-
cial interest, since they allow conclusions about the bind-
ing aﬃnity of the compounds. Regarding the integration
of secondary databases like SCOP (12), CATH (13) and
Pfam (14), there is a variety of excellent sources with a
strong focus on macromolecules, like PDBsum (15),
RCSB PDB (1) and IMB Jena Image Library (16), while
PROCOGNATE (17) is especially tailored for elucidating
enzymatic activity. However, there is no single resource,
which is centered on drug-like compounds, while integrat-
ing all available structural information. Therefore, Super-
Site was created with three main design goals in mind:
 Rich integration of the PDB, including full-text
search, complete 3D information and extraction of
ligand–receptor relationships.
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binding sites.
 Detection and highlighting of compounds, which are
considered to be medically active.
The aim of SuperSite therefore is, to assist the structural
biologist with an online tool, which facilitates the inspec-
tion of known and putative binding sites, regarding likely
binding sites and conservation information. For drug-like
compounds, we are additionally providing superimposed
binding sites of the same ligand, which allows the detec-
tion of structurally conserved residues.
DATABASE AND TOOLS
Primary database
SuperSite’s main data source is the PDB, currently con-
taining over 51000 3D structures and providing well over
290000 implicit interactions of macromolecules and small
compounds. The raw PDB is parsed and translated auto-
matically into a relational database schema that enables
SuperSite to further integrate secondary databases for
information enrichment (see subsequent subsection). To
make the knowledge in the primary database accessible,
SuperSite is providing extensible means for querying. The
main text query possibilities include the search for PDB-
ID, Het-ID, protein, ligand names and synonyms, as well
as a full text search, which screens the complete header of
all PDB ﬁles for a given term. For instance, searching for
the term ‘insulin’ reveals all insulin-related proteins so that
they can be used for further investigation. An important
subgroup of the proteins in the PDB, are enzymes
involved in many catalytic activities. To this end, Super-
Site provides an EC tree presentation (18), which makes it
possible to browse the PDB via enzyme class/subclass and
picking proteins of interest. To investigate the similarity of
certain proteins, we have integrated the protein similarity
cluster information from the Cd-hit algorithm (18). This
information is provided for 95, 90, 70 and 50% similarity,
based on the sequence. A specialized search form not only
allows the search for similar proteins, but also allows
searching for apo-/holo-states. This directly allows to
deal with the question, how much the bound form of a
protein diﬀers from the unbound form. When it comes to
the ﬁeld of small compounds in the PDB, SuperSite is
providing appliances for ﬁltering physio-chemical features
like molecular weight, chemical formula or number of
atoms. A built-in tool for ﬁnding similar small ligands
to a given one, is a ﬁngerprint search, based on
MyChem ﬁngerprints (http://mychem.sf.net). SuperSite
also provides Marvin as an online tool (http://www.che
maxon.com/), which allows to draw or upload a molecule,
and screen it against all ligands contained in the PDB (sdf
and mol ﬁle formats are supported). User-deﬁned com-
pounds are visualized by a superposition according to
the most similar bound ligand.
Secondary datasources
To assist the user in investigating potential binding part-
ners and putative binding pockets, SuperSite integrates
secondary information from related data sources. Ana-
lyses of functionally important sites suggest that the
degree of conservation within a protein family is a hint
for potential binding sites (19). To this end, SuperSite
integrates information from HSSP (20), a data source,
which contains information about the degree of residue
conservation within a family of proteins. As additional
source of information, we are providing de novo predic-
tions of possible protein binding pockets calculated by
LIGSITEcsc (21). This information is precalculated
and also stored in the database. HSSP and LIGSITEcsc
provide exhaustive information about putative binding
sites. Together with the possibility to elucidate related pro-
teins (as described in the subsection above), this provides
starting points for the detection of putative binding sites.
Drug site encyclopedia
A subset of all relations, between proteins and small com-
pounds, is the relationship of proteins and drugs. This
subset is of high importance, when it comes to a systema-
tic investigation of the desired eﬀects of drugs (on- and
oﬀ-target eﬀects). An implemented part of SuperSite
therefore is the Drug Site Encyclopedia. As the term
drug is not self-deﬁning, we compared the World Drug
Index (http://scientiﬁc.thomsonreuters.com), the Compre-
hensive Medical Chemistry (CMC) Database (http://
www.mdl.com), the NCI cancer Compounds (http://
dtp.nci.nih.gov) and SuperDrug (22) with all ligands of
the PDB to determine the intersection set using stan-
dard ﬁngerprints from OpenBabel (http://openbabel.org).
The screening was performed via a ﬁngerprint search
(http://mychem.sf.net). Entities with a Tanimoto coeﬃ-
cient of >0.85 and an equal number of nonhydrogen
atoms were considered as drugs (23). This screening
yielded more than 1300 medicinal compounds in the
PDB. Within the Drug Site Encyclopedia, we are provid-
ing extended instruments for exploring the relationship
between drug and target. One aspect is the possibility to
investigate the superimposed binding sites of the same
ligand, showing residues that are conserved in a spatial
region, or frequently occur in a region characteristic for
drug recognition. Additionally, we are providing a point
set match algorithm, which uses known binding sites
(patches) of a ligand, to recognize similar patches on the
surface of uploaded structures—solved structures or
models (algorithm to be published elsewhere). SuperSite
is also calculating Lipinski’s Rule Of Five (24), reﬂecting
the drug-likeness of uploaded or edited compounds.
Visualization, browsing and availability
SuperSite can be used with a standard web browser with
active Java 1.5+. The molecular viewer Jmol (http://jmol.
org) visualizes proteins, ligands and interactively high-
lights all integrated data sources like HSSP or
LIGSITEcsc. SuperSite also allows browsing between
ligand and protein interactions, and vice versa. For
instance, it is possible to query the protein ‘Insulin’, pick
out a ligand and jump to the next view providing all co-
crystallized proteins. If the ligand is contained in the Drug
Site Encyclopedia, it is also possible to investigate the
D196 Nucleic Acids Research, 2009, Vol. 37, DatabaseissueFigure 1. Superimposed binding sites of the ligand Vitamin B6 (Het-ID: PLP) from PDB-IDs: 1BJO, 1C7N and 1DJE. Although the proteins show
an overall dissimilar structure, residue glycine (red), lysine (blue) and histidine (green) are clustering at speciﬁc spatial positions (other atoms of the
binding sites depicted in gray).
Figure 2. An apo (PDB-ID: 1WDP, A) and holo form (PDB-ID: 1B1Y, B)o fb-amylase. The predictions for the binding site pocket (green) as well
as the HSSP conservation (red conserved, white not conserved) support the hypothesis of a binding site at this position. This claim can be proved by
the holo form (B) with a-D-glucose (blue), bound to the predicted pocket.
Nucleic Acids Research, 2009,Vol. 37,Database issue D197superimposed binding sites. Links are provided to numer-
ous relevant sources, containing further specialized data
sources [e.g. Proteopedia (25), RCSB, PDBSum].
SuperSite is accessible free of charge for academic
institutions. Flat ﬁles of the database are available upon
request.
CASE STUDIES
Case study 1: PLPbinding partnersand spatial mining
Vitamin B6 (Het-ID: PLP) is a co-enzyme, mainly used in
the amino acid metabolism and widely present in the
human body. Currently, SuperSite contains information
Figure 3. A dihydrofolate reductase (PDB-ID: 1RA7) with folic acid (HET-ID: FOL, red) bound. One of the highest ranking results from a ligand
similarity screening, using compound Methotrexate (Het ID: MTX, blue), suggests a binding at that position.
D198 Nucleic Acids Research, 2009, Vol. 37, Databaseissueabout 463 structures containing PLP, representing, a vari-
ety of proteins (e.g. aminotransferases, glycogen phos-
phorylases). A visualization of all binding sites at once
can be achieved, by selecting ‘Drug Encyclopedia’ in the
main menu and then entering ‘PLP’ as Het-ID. This view
allows inspecting common features, like spatial conserva-
tion of speciﬁc amino acid types. In the case of PLP, it gets
obvious, that, for instance, residue Gly is conserved at a
spatial position near the phosphate (Figure 1). This is even
the case, when the proteins are structurally dissimilar, a
conclusion also discussed in ref. (26).
Case study 2: determination of binding pockets
The elucidation of possible binding pockets and active
sites of proteins without co-crystallized compounds is a
common task for structural biologists. SuperSite provides
two tools for the investigation into this topic:
LIGSITEcsc—providing precalculated binding pocket
predictions and HSSP—providing information about
sequence conservation. For instance, PDB-ID 1WDP
refers to the structure of the enzyme b-amylase, solved
without substrate. To evaluate if there is a possible bind-
ing pocket, the user can consult LIGSITEcsc and HSSP
interactively from SuperSite (Figure 2). The HSSP conser-
vation shows a more conserved region around residue
glutamine (residue number 186). At the same position,
LIGSITEcsc shows a relatively large predicted binding
pocket. There is another b-amylase (PDB-ID: 1B1Y) simi-
lar in overall structure to the apo form containing a ligand
at the position proposed by LIGSITEcsc and HSSP what
shows the applicability of this method.
Case study 3: detection ofbinding partnersvia similarity
screening
SuperSite also oﬀers a facility for the fast similarity screen-
ing of a compound, against all ligands co-crystallized in
the PDB. This enables to hypothesize about possible bind-
ing partners for similar compounds. Methotrexate (Het-
ID: MTX) is a drug, which is used as anti-inﬂammatory
agent/immunosuppressant and in high concentrations
used as chemotherapeutical agent (27). Methotrexate
inhibits the folic acid biosynthesis and therefore slows
the proliferation of cells. SuperSite enables the user to
ﬁnd similar compounds in the PDB, by simply drawing,
or by uploading a mol or sdf ﬁle. After issuing the simi-
larity search for Methotrexate, one of the best hits not
identical to Methotrexate, is folic acid (HET-ID: FOL)
bound to a dihydrofolate reductase (Figure 3). The
query compound Methotrexate is superimposed with
folic acid, which is the known mode of action.
CONCLUSIONS
We presented a novel database, SuperSite that oﬀers 3D
information about proteins and about their bound com-
pounds (ligands). SuperSite enables the user to investigate
into the relationship of ligand and receptor in atomic
detail, integrating information sources about putative bin-
ding sites and conservation on residue level. SuperSite is
made with an emphasis on ligands, that are drug-like and
therefore of special interest for medical research. To this
end, SuperSite provides 3D superpositions of all binding
sites of a certain ligand, which enable the user to investi-
gate into the spatial arrangement and properties of the
binding site. For further investigations, SuperSite allows
to issue a similarity screening against ligands bound in
macromolecules as well as a screening of proteins against
known binding sites. SuperSite is publicly available at:
http://bioinformatics.charite.de/supersite.
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